(IMRX)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer |
| Dr. Peter King Ph.D. | Head of Discovery & VP |
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology & VP |
| Mr. Michael D. Bookman J.D. | Chief Legal Officer & Secretary |
| Mr. Robert J. Carpenter M.B.A., M.S. | Co-Founder & Chair Emeritus |
| Ms. Courtney Dugan | VP and Head of Investor Relations & Corporate Communications |
| Date | Type | Document |
|---|---|---|
| 2026-03-06 | 10-K | imrx-20251231.htm |
| 2026-01-07 | 8-K | imrx-20260107.htm |
| 2025-11-12 | 8-K | imrx-20251112.htm |
| 2025-09-25 | 8-K | tm2526946d1_8k.htm |
| 2025-09-24 | 8-K | tm2526843d1_8k.htm |
| 2025-09-09 | D | |
| 2025-09-04 | CORRESP | filename1.htm |
| 2025-09-03 | S-3 | tm2524971-1_s3.htm |
| 2025-08-25 | 8-K | tm2524079d1_8k.htm |
| 2025-08-18 | CORRESP | filename1.htm |
| Ms. Leah R. Neufeld | Chief People Officer |
| Ms. Mallory Morales CPA | Senior VP of Finance, Chief Accounting Officer & Treasurer |
| Ms. Paula George CPA | Director of Accounting & Operations and Assistant Corporate Controller |